Looking for a new broker?
Ambrx Biopharma, Inc. stock is up 14.79% since 30 days ago. The next earnings date is Aug 28, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 4 PUTs, 6 CALLs. 67% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 18 Oct 19:56 | 17 Nov, 2023 | 7.50 | 424 | ||
| 19 Oct 17:15 | 19 Jan, 2024 | 12.50 | 149 | ||
| 19 Oct 17:36 | 17 Nov, 2023 | 7.50 | 50 | ||
| 19 Oct 17:36 | 17 Nov, 2023 | 7.50 | 50 | ||
| 23 Oct 13:48 | 17 Nov, 2023 | 10.00 | 5301 | ||
| 23 Oct 18:59 | 17 Nov, 2023 | 10.00 | 157 | ||
| 06 Nov 16:42 | 19 Apr, 2024 | 10.00 | 71 | ||
| 07 Nov 15:33 | 17 Nov, 2023 | 10.00 | 3806 | ||
| 14 Nov 17:58 | 17 Nov, 2023 | 10.00 | 797 | ||
| 15 Nov 15:19 | 19 Apr, 2024 | 10.00 | 93 |
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.
